Science News
After More Than a Decade, Colombia's 'Holy Grail' Poison Dart Frog Reaches the Legal Market for the First Time
FOR IMMEDIATE RELEASE After More Than a Decade, Colombia’s “Holy Grail” Poison Dart Frog Reaches the Legal Market for the First Time Tesoros Frogs releases the first captive-bred Oophaga sylvatica “Koi” ever legally available to keepers, the result of a conservation program built to undercut smugglers, not to profit from rarity. CUNDINAMARCA, Colombia — For the first time, one of the most sought-after poison dart frogs in the world is available to keepers through legal, captive-bred origin. Tesoros Frogs, Colombia’s only licensed conservation-breeding program of its kind, has released the first captive-bred Oophaga sylvatica “Koi” ever offered, with additional frogs expected through the program’s regular shipments. The milestone caps more than ten years of work, and is widely misunderstood. Tesoros began with a shipment of dying frogs. In 1998, Colombian police called Ivan Lozano, then director of Bogotá’s wildlife rescue center, about two suspicious boxes at El Dorado International Airport bound for Europe. Inside were nearly 800 poison dart frogs crammed into tiny containers. Most were dead or dying by the time he arrived. His response was to attempt what no one in Colombia had: breed the most-trafficked species legally and sell them for less than smugglers could, until the illegal trade stopped making financial sense. The cost of that effort is a matter of public record. As reported by National Geographic, Lozano’s business partners withdrew their support, leaving him with 2,000 frogs, no license, and roughly USD 400,000 in debt. Obtaining the license took nearly a decade. The Associated Press reported that the first export permit alone took three years, and that the program has struggled to keep prices low because of permitting costs. Tesoros has come close to failing more than once. “People see a rare frog and assume there is a fortune behind it. The truth is the opposite. What it costs to bring one of these animals out legally, over years, is far more than what it returns. We do this because if we do not, these species get taken from the forest instead.” — Ivan Lozano, founder of Tesoros Frogs The clearest evidence of the program’s purpose is what has happened to prices. The golden poison frog, among the most heavily trafficked species, sold for around USD 150 before Tesoros began exporting; today it can be obtained legally for under USD 35. U.S. breeders and collectors report the market for wild-caught Colombian poison dart frogs has diminished significantly. That decline is the goal, not a side effect: the aim, as Lozano has put it, is for prices to fall so far that trafficking these frogs is no longer profitable. Oophaga sylvatica is classified as Near Threatened, pressured by illegal overcollection and habitat loss. The “Koi” takes its name from its resemblance to ornamental koi fish, and no two individuals share the same pattern. Long among the most desirable frogs in the hobby, it has until now been unavailable from any legal captive-bred source, leaving keepers who wanted one to choose between going without and buying an animal of unknown origin. Conservation breeding of this kind runs on far thinner margins than most assume and depends on outside support. Readers who want to support amphibian conservation in Colombia can do so through Active Conservation Alliance , a US-based 501(c)(3) nonprofit funding habitat protection and community conservation work across the country. Ivan Lozano serves on its board. About Tesoros Frogs: Tesoros Frogs (Tesoros de Colombia) is a Colombia-based conservation-breeding program producing legally sourced, captive-bred poison dart frogs as an alternative to the illegal wildlife trade. It remains the only licensed commercial breeding operation of its kind in Colombia. More at tesorosfrogs.com . Media Contact: Michael Heinrich, Founder, Active Conservation Alliance | [email protected] | [720] 688 - 9000 | tesorosfrogs.com
Creative Diagnostics Expands Preclinical Portfolio with Characterized Peritoneal Fibrosis Models for Renal Research
Vanuatu Shoreline Loss Signals Global Climate Risk From Rising Heat
Ever Wonder Adventure Backs Food Waste Energy As Europe Faces Extreme Heat Today
- July 16, 2026Science
Creative Biolabs Accelerates CRISPR Research with Integrated Gene Editing Solutions
CRISPR technology has transformed genome engineering, yet many research teams still encounter technical obstacles that delay project timelines and limit experimental success. Inefficient delivery systems, inconsistent editing performance, lengthy cell line development, and fragmented service workflows remain persistent challenges across gene therapy, disease modeling, and functional genomics research. To help researchers overcome these barriers, Creative Biolabs offers an integrated portfolio of CRISPR-assisted gene editing solutions that streamlines every stage of genome engineering—from experimental design and delivery optimization to engineered cell line generation and downstream validation. One of the most significant hurdles in CRISPR research is achieving efficient delivery to intended cell types of editing components. Delivery strategies must balance editing efficiency, cell specificity, scalability, and safety while limiting cytotoxicity and unintended editing. Creative Biolabs provides customized CRISPR delivery agent construction services, including viral vector engineering, lipid nanoparticle (LNP) formulation, guide RNA cloning, and donor vector development, enabling researchers to select delivery approaches tailored to their experimental objectives. Another common bottleneck is the development of reliable engineered cell models. Commercial cell lines often fail to match specific research requirements, forcing laboratories to spend months generating customized models. Creative Biolabs addresses this challenge with CRISPR-assisted cell line development services that support gene knockout, knock-in, point mutation, Cas9 overexpression, and CRISPRa/CRISPRi platform construction. Each project includes customized design, clone screening, validation, and quality documentation to help researchers move confidently into downstream applications such as disease modeling, drug discovery, and functional screening. Beyond individual services, Creative Biolabs integrates multiple CRISPR capabilities into a unified workflow. Researchers can access gene editing, delivery optimization, cell line engineering, CRISPR screening, nuclease activity measurement, and library design through a single scientific partner, which may reduce project complexity and improving research continuity. This comprehensive approach helps laboratories shorten development timelines while maintaining high experimental quality. "As CRISPR applications continue expanding across gene therapy and precision medicine, researchers need more than isolated technical services," said a scientific representative from Creative Biolabs. "They need integrated solutions that address real-world experimental challenges from beginning to end. Our goal is to help clients generate reliable results faster while managing technical risks throughout the research process." By combining advanced genome editing expertise with customizable service platforms, Creative Biolabs continues to support academic institutions, biotechnology companies, and pharmaceutical organizations worldwide in accelerating innovation across gene editing and therapeutic development. Learn more about Creative Biolabs' CRISPR solutions: https://www.creative-biolabs.com/gene-therapy/crispr-assisted-gene-editing-solutions.htm. About Creative Biolabs Creative Biolabs provides customized CRISPR gene editing, delivery optimization, and engineered cell line development services, empowering global researchers with integrated solutions for gene therapy, functional genomics, and biomedical innovation.
- July 8, 2026Science
Colorado Wildfire & Disaster Preparedness Book With Real Examples Released
HieroGraphics Books has released 'Lessons From Colorado Fires & Flood: Encouraging and Informative Stories to Help You Prepare for and Survive Natural Disasters,' a 274-page book that draws directly from the 2012 Waldo Canyon wildfire and the 2013 floods that struck the Pikes Peak region. Penned by author Julia L. Wright, the book combines actionable preparedness strategies with documented accounts of how Colorado communities, residents, and government agencies responded to back-to-back natural disasters that disrupted the region for two consecutive years. More information is available at https://www.amazon.com/dp/0996581642 The timing of this publication reflects a growing national trend, as America has experienced increasingly extreme and intense fires and flooding over the past decade. The 2012 wildfire in the Pikes Peak area destroyed wilderness and roared through a nearby subdivision, consuming homes and threatening livelihoods, only for a series of floods to repeatedly challenge the region, interrupting summer tourism and daily life while forcing communities to confront the economic and environmental consequences of consecutive disasters. Wright brings a uniquely local perspective to the book, having lived through the 2012-2013 disasters as a resident of a small Colorado mountain town. Her firsthand experience with the community's response and recovery efforts informs every chapter, ensuring that the advice reflects genuine collaboration between citizens and government agencies. The book integrates preparedness checklists with encouraging real-life recovery stories, transforming disaster readiness from an anxious, theoretical exercise into an informed and empowering process. Wright emphasizes that the best way to face a natural disaster comes from a place of knowledge rather than fear, and her book aims to share information that helps readers prepare themselves and survive when confronted with any natural disaster they might experience. By documenting how the Pikes Peak community responded, recovered, and collaborated across multiple sectors, the book positions disaster preparedness as a realistic and achievable goal grounded in proven human resilience and problem-solving. The book joins a range of other publications from Wright, which cover topics related to the natural world and other forms of preparedness. Colorado residents in high-risk wildfire and flood zones, as well as anyone interested in natural disaster preparedness grounded in real-world examples, can get the book through major retailers including Amazon and through the HeiroGraphics digital storefront at the link below. For additional information about HieroGraphics Books and its publications, visit https://www.hierographicsbooks.com
- June 28, 2026Science
Food Waste To Energy Gains Urgency As London Faces Extreme Heat
London’s latest extreme heat warning has turned climate change from an abstract forecast into a visible public safety issue. Across Europe, record-breaking temperatures are closing schools, disrupting transport, stressing power systems, and raising health risks for older residents, outdoor workers, children, and people with existing medical conditions. The heatwave is also renewing public focus on greenhouse gas emissions from food waste. Climate scientists have reported that human-driven global warming has made recent European heatwaves significantly hotter than they would have been in the past. While fossil fuels remain central to the climate crisis, food waste is also a major contributor to emissions. Globally, large volumes of food are lost between farms, supply chains, retailers, restaurants, and households. When wasted food decomposes in landfills, it produces methane, a powerful greenhouse gas that accelerates warming. This makes food waste reduction one of the most immediate and practical climate actions available. Unlike many industrial transitions that require decades of infrastructure change, food waste can be reduced through better meal planning, improved supply chain logistics, clearer date labelling, surplus food sharing, responsible purchasing, and food recovery programmes. These steps reduce emissions while also lowering costs and improving access to nutrition. Ever Wonder Adventure is highlighting the link between food waste, climate change, and Europe’s intensifying heat through its public awareness resource at https://everwonderadventure.com/stop-food-waste . The campaign frames wasted food as a climate, economic, and social issue. Food that is thrown away represents wasted land, water, fertiliser, transport fuel, refrigeration energy, labour, and money. The final environmental impact is intensified when that waste produces methane. The current heatwave demonstrates why action matters. London’s buildings, roads, rail systems, and public services were not designed for repeated extreme temperatures. As warmer nights reduce the body’s ability to recover from daytime heat, public health risks increase. Climate adaptation is becoming more expensive, and prevention remains essential. One promising pathway is turning unavoidable food waste into electricity through anaerobic digestion. This process breaks down organic matter without oxygen, producing biogas that can be used for renewable energy. Instead of allowing food waste to rot in landfills, communities can capture its energy value and reduce harmful emissions. The remaining digestate can support soil health, helping close the loop between food production, waste management, and agriculture. This is the foundation of a circular economy. Organic waste is redirected from landfills, converted into clean energy, and returned to productive use. For cities facing climate stress, anaerobic food waste transformation can support local energy resilience, waste reduction, and lower greenhouse gas emissions. Ever Wonder Adventure’s environmental mission, supported through https://everewonderadventure.com/support-us , encourages practical public engagement with climate solutions, conservation, and sustainable living. Its message is that climate action must move beyond awareness into everyday systems. Europe’s heatwave is a warning that greenhouse gas emissions already carry direct consequences. Reducing food waste, recovering surplus food, and converting unavoidable organic waste into renewable electricity can help address global warming while building a more resilient, resource-efficient future.
- June 26, 2026Science
Creative Diagnostics Launches Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics
Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has officially launched its new TriLS™ Tritosome product line. Derived from mouse and rat liver tissues, these high-purity, surfactant-modified lysosomal fractions can provide drug discovery teams with a robust, highly reliable in vitro model for evaluating lysosomal stability, trafficking, and payload release. Lysosomes are essential organelles in eukaryotic cells that are responsible for a variety of functions, including endocytic degradation, extracellular secretion, and signal transduction. Dozens of proteins are localized to the lysosomal membrane, where they regulate the transport of ions and substances across the membrane. These proteins are crucial to lysosomal function. Mutations or abnormal expression of these proteins can trigger various diseases, making them potential targets for the development of drugs aimed at treating lysosomal disorders. However, further breakthroughs in this field of research require a deeper understanding of the underlying mechanisms by which abnormalities in these membrane proteins induce associated diseases. As complex drug modalities such as antibody-drug conjugates (ADCs) and oligonucleotide therapies (including mRNA, siRNA and circular RNA) dominate the preclinical development pipeline, it is of paramount importance to understand their intracellular fate. A major bottleneck in these workflows is the in vitro simulation of the lysosomal environment. Due to physical density overlap, standard differential centrifugation often contaminates lysosomal fractions with mitochondria, which distorts metabolic and pharmacokinetic data. To support this research, Creative Diagnostics has overcome this technical challenge with its TriLS™ Tritosome separation technology. This technology uses the tissue-specific endocytosis of the non-ionic surfactant Tyloxapol (Triton WR-1339) to selectively alter the buoyant density of target lysosomes. This enables pure, high-resolution separation via density gradient centrifugation, effectively removing over 90% of mitochondrial cross-contamination while preserving active lysosomal hydrolases. The Tritosomes supplied by Creative Diagnostics play a key role in advancing research into ADCs by providing a pure model for the study of lysosomal uptake, processing, and payload release. Tritosomes enable researchers to gain in-depth knowledge of linker chemistry, cleavage efficiency, payload release patterns and species-specific differences in drug release. This helps to optimize the stability and efficacy of ADCs, achieving better therapeutic outcomes. A key challenge in the research of small-molecule nucleic acid drugs is that most oligonucleotides are captured by endosomes and lysosomes. If they cannot escape these organelles and enter the cytoplasm, they are rapidly degraded and lose their therapeutic activity. Against this backdrop, Creative Diagnostics' Tritosomes provide a controlled in vitro system for studying the degradation kinetics of unmodified and chemically modified nucleic acid drugs. Researchers can use these Tritosomes to evaluate the protective effect of chemical modifications against lysosomal degradation and assess the efficacy of delivery systems designed to facilitate endosomal escape. Consequently, Creative Diagnostics' Tritosomes are crucial for optimizing drug stability and refining delivery strategies prior to progressing to more complex animal models. To explore technical specifications, review workflow diagrams, or request a quote, please visit the official product page at https://qbd.creative-diagnostics.com/trils-tritosome.html . About Creative Diagnostics Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.
- June 25, 2026Science
CD Bioparticles Launches Advanced Microneedle Device Customization Services to Accelerate Transdermal Drug Delivery Innovation
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its comprehensive Microneedle Device Customization Services. This modular platform has integrated cutting-edge micro-fabrication equipment, advanced material engineering, and analytical validation systems to help biotechnology companies and research institutions to seamlessly scale microneedle therapies from bench-top prototypes to clinical-grade pilot production. Microneedles (MNs) are micrometre-scale needles that range in height from 25 to 2,000 micrometres. They are manufactured from a variety of materials and are available in a range of shapes. Microneedle technology is a recent advancement in biomedical science. MN-based drug delivery technology can overcome many of the limitations currently faced in drug delivery, including low absorption rates, low bioavailability, insufficient skin permeability and poor biodistribution. Nanotechnology has significantly transformed microneedle manufacturing processes, shifting from traditional to innovative designs and incorporating various natural and synthetic materials, as well as combinations thereof. Due to its multifaceted and extensive application prospects, microneedle technology has gained widespread popularity in the fields of global biomedical research and drug delivery technology. CD Bioparticles now offers customized microneedle manufacturing equipment and modular production systems to support the entire development process, from early-stage research to pilot-scale production. The company's solutions include laboratory-scale experimental systems (bench-top equipment) for formulation screening and process development, as well as pilot-scale production systems for process validation and small-batch manufacturing. CD Bioparticles' microneedle equipment is built on industrial-grade, high-frequency, impact-jet fluid control technology, and is specifically designed for the precise filling of microneedle tips and coating of substrate materials. The system ensures stable and accurate fluid delivery through the coordinated operation of high-precision core modules. In addition, all components support modularity and flexible customization, including adjustable micro-nozzles and liquid reservoirs of various sizes. The system is fully compatible with a wide range of high-viscosity polymer formulations, including PVP, PVA, HA and PLGA, and is suitable for various microneedle array designs. The custom development process comprises four steps, including 1)requirement evaluation (microneedle product evaluation and manufacturing process analysis); 2) engineering design & system development; 3) equipment manufacturing (machining of core components, automation system integration, software control system integration, and internal mechanical calibration); 4) delivery & technical support (on-site installation and commissioning of microneedle equipment, operator training, and remote technical support for up to one year). CD Bioparticles' microneedle manufacturing systems are widely used for cosmetic microneedle patches, vaccines, exosome delivery systems, peptide delivery platforms, transdermal drug delivery, biologics development, aesthetic skincare products, and medical device manufacturing. CD Bioparticles assists clients in establishing stable, reproducible and scalable microneedle manufacturing platforms to meet their diverse application requirements, from prototype development to pilot production. For more details regarding CD Bioparticles' Microneedle Device Customization Services or to request technical specifications for available micro-fabrication platforms, please visit https://www.cd-bioparticles.net/services/microneedle-device-customization-services.html . About CD Bioparticles CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.
- June 25, 2026Science
STEMart Expands Analytical Equipment Portfolio with Flowmeter Solutions for Bioprocess and Laboratory Applications
STEMart, a US-based provider of comprehensive services for all phases of medical device development, is excited to announce the expansion of its analytical instrumentation portfolio with the launch of its advanced Flowmeter category line. This specialized product expansion can meet the rigorous demands of modern laboratories, pilot plants, and bioprocessing facilities requiring ultra-precise fluid and gas dynamic monitoring. A flowmeter is an instrument used to measure the flow rate of liquids, gases, steam, powders, or mixtures of these substances passing through pipes or conduits. It can measure linear flow, non-linear flow, mass flow, or volumetric flow. The core operating principle determines the basic types of flow meter. Flowmeters fall into two main categories: energy-additive and energy-extractive. Energy additive flowmeters introduce energy into the flowing medium to determine the flow rate, whereas energy-extracting flowmeters extract energy (usually in the form of a pressure drop) from the flowing medium. Common types of flowmeters used in industrial applications include turbine, electromagnetic, positive displacement, pressure-type, variable-area, hydrodynamic, vortex, anemometer, Coriolis, laser Doppler, sonar, optical and ultrasonic. In the research environments, precise flow control is important for accurate results. However, fluctuations in the delivery of gases or liquids can affect cell culture viability, the reproducibility of chromatographic analyses and the outcomes of chemical synthesis directly. To support the research and industrial applications, STEMart has launched flowmeters to address these challenges by offering robust, high-precision instruments to deliver exceptional long-term stability and minimal drift. This new product portfolio features a variety of operating principles to meet specific research and industrial requirements. STEMart, for example, offers the MFE800-S Electromagnetic Flowmeter (CAT#: STEM-AIAE-0553-ZJF), which uses the principle of electromagnetic induction to measure conductive liquids and liquid-solid mixtures. The device requires a conductivity of over 5 μS/cm, making it suitable for a wide range of industrial applications, including the measurement and monitoring of liquid, gas, and steam flow in the industrial and municipal sectors. As there are no obstructions to the flow or moving parts within the measuring tube, this product eliminates additional energy loss and prevents blockages, resulting in significant energy savings. It is particularly well-suited to measuring two-phase liquid-solid flows, such as sewage, slurry, ore slurry, coal slurry and pulp. Furthermore, only the lining and electrodes come into contact with the measured medium. By selecting suitable lining and electrode materials, excellent corrosion and wear resistance can be achieved. Consequently, a wide range of chemical solutions, including strong acids and alkalis, can be measured. For more information regarding technical specifications, bulk ordering, or to view the full product selection, please visit the official STEMart category page at https://www.ste-mart.com/category-flowmeter-1603.htm . About STEMart STEMart is an industry-leading eCommerce platform incorporated with an extensive global footprint and a broad portfolio of more than 10,000 products. It aims to provide better lab materials, medical instruments and consumables, excellent technologies, and high-quality services to global customers in the fields of science, technology, and engineering, from the discovery stage upward to the manufacturing process. STEMart is dedicated to enhancing research and biotech production with simpler and safer protocols to access better health worldwide.
- June 22, 2026Science
Creative Biolabs Empowers Researchers to Overcome Hurdles in Complement Drug Development
Complement-targeted therapeutics have emerged as one of the fastest-growing areas in immunology drug development, with a surge of interest in treatments for autoimmune disorders, kidney diseases, neurological conditions, and rare diseases. However, accurately evaluating complement activation, pathway function, and therapeutic efficacy remains a major challenge for researchers seeking to advance promising drug candidates. Researchers developing complement inhibitors and other complement-targeted therapies often face obstacles such as inconsistent assay performance, limited pathway-specific testing options, and difficulties correlating complement activity with therapeutic outcomes. These challenges can delay candidate selection and increase development costs. To address these needs, Creative Biolabs has expanded its complement testing portfolio, providing researchers with specialized solutions for complement pathway analysis, complement inhibitor screening, and functional evaluation throughout the drug development process. The company's capabilities include: • Complement activation assays for the classical, alternative, and lectin pathways • Complement component analysis, including C1q, C3, C4, and related biomarkers • Complement function assays for therapeutic evaluation • Complement inhibitor screening and pharmacodynamic studies • Customized assay development tailored to specific research objectives Among the featured solutions is the CH50 functional test kit , a hemolysis-based assay designed to quantitatively measure classical complement pathway activity. The kit supports serum and plasma samples from multiple species, providing researchers with a reliable tool for complement function assessment and therapeutic candidate screening. Creative Biolabs also offers hemolysis assay for solutes services to evaluate the hemolytic potential and biocompatibility of compounds, biologics, and formulations. These studies help researchers identify potential safety concerns and better understand complement-mediated cellular responses during preclinical development. "As more organizations invest in complement-targeted therapeutics, the demand for reliable functional assays continues to grow," said a spokesperson from Creative Biolabs. "Our goal is to provide researchers with actionable data that supports candidate selection, mechanism-of-action studies, and preclinical decision-making." Researchers worldwide continue to utilize Creative Biolabs' expertise to accelerate complement research programs. "We needed a reliable CH50 assay to compare multiple complement inhibitors. The assay reproducibility and technical support exceeded our expectations." — Immunology Scientist, U.S. Biotechnology Company "The hemolysis data helped us identify formulation-related safety concerns before advancing to later-stage studies, saving significant development time." — Preclinical Research Director Researchers interested in evaluating complement activation, complement inhibitor efficacy, or hemolytic activity can consult with Creative Biolabs specialists to discuss project-specific testing strategies. To learn more, please visit https://www.creative-biolabs.com/complement-therapeutics/ . About Creative Biolabs Creative Biolabs is a biotechnology company with a strong focus on complement therapeutic research, offering specialized platforms and services that accelerate the discovery, characterization, and optimization of complement‑targeted drugs. The company provides integrated solutions spanning complement pathway analysis, inhibitor development, functional assays, and translational studies, enabling researchers to explore mechanisms of complement activation and advance next‑generation complement‑based therapeutics.
- June 18, 2026Science
Consumer Demand for Product Transparency Continues to Grow Across the Botanical Products Industry
As consumers become increasingly informed about the products they purchase, transparency has emerged as one of the most important factors influencing buying decisions across the botanical, supplement, and wellness industries. Today's consumers have greater access to information than ever before and are increasingly seeking detailed product information before making a purchase. From ingredient sourcing and manufacturing standards to independent laboratory testing and product verification, transparency is becoming a key trust signal for brands operating in competitive consumer markets. Super Speciosa , a U.S.-based botanical products company, believes this shift reflects a broader movement toward accountability and informed decision-making among consumers. "Consumers today expect more than marketing claims. They want access to information they can review and verify for themselves," said Super Speciosa. "Transparency helps build trust and allows consumers to make purchasing decisions with greater confidence." Super Speciosa provides consumers with access to batch-specific laboratory reports through a comprehensive product traceability system. Every product is assigned a unique batch number and includes a QR code that allows customers to quickly access the corresponding laboratory results for the exact batch they purchased. This approach provides a level of transparency and verification that remains uncommon across much of the broader supplement and botanical products marketplace. As demand for transparency continues to grow, many consumers are placing increased value on third-party testing and product-specific verification systems that provide insight into product quality and consistency. To help meet these expectations, Super Speciosa provides access to batch-specific laboratory testing information for products distributed through its website. Testing is conducted by independent third-party laboratories accredited to the ISO/IEC 17025 standard, a globally recognized benchmark for laboratory competence and quality assurance. By making this information available to consumers, Super Speciosa enables customers to review detailed testing data associated with individual product batches. As consumer expectations continue to evolve, Super Speciosa believes transparency must be supported by rigorous quality standards. Every batch undergoes a comprehensive testing panel conducted by independent third-party laboratories, including screening for microbial contaminants such as Salmonella and harmful bacteria, heavy metals, mold, and verification of multiple naturally occurring alkaloids. The company follows National Sanitation Foundation (NSF) standards for dietary supplements and maintains a strict quality assurance process in which any batch that does not meet established standards is discarded and never offered for sale. Industry observers note that transparency initiatives are becoming more common as consumers seek greater visibility into the products they purchase and the standards behind them. Brands that invest in verification systems and independent testing may be better positioned to meet evolving consumer expectations. "Transparency is no longer viewed as a competitive advantage by many consumers—it is increasingly becoming an expectation," Super Speciosa added. "The companies that prioritize accessibility, accountability, and verification are helping shape the future of the industry." As consumer awareness continues to grow, Super Speciosa expects demand for independent testing, product traceability, and quality verification to remain important factors influencing purchasing decisions throughout the botanical products sector. For more information, visit https://superspeciosa.com/ Super Speciosa is a U.S.-based botanical products company committed to transparency, quality, and consumer education. Through third-party laboratory testing and product verification initiatives, the company works to provide consumers with greater access to information about the products they purchase. Contact Information: Super Speciosa 7901 4th St N Ste 300 St. Petersburg, FL 33702 United States Email: [email protected] Website: https://superspeciosa.com/
- June 16, 2026Science
Inzecto Announces Newly Granted Upgraded EPA Registration Providing Three Months of Continuous Mosquito Control
INZECTO , a developer of Pest Management technologies, announces that the United States Environmental Protection Agency (EPA) has granted an upgraded label registration for the company’s proprietary mosquito trap. This updated regulatory milestone extends the recognized duration of continuous insect control from 35 days to a period of three months. The regulatory upgrade allows public and private pest management entities to implement year-round mosquito management options with quarterly services. Essentially, this device now simplifies the challenges associated with mosquito and mosquito-borne disease management. “This concludes a long and meticulous scientific evaluation process with federal regulators,” states Enrico Levi, founder and CEO of INZECTO. “This newly updated registration validates the duration of the technology using rigorous testing protocols in the US as well as internationally.” Enrico Levi Another major modification on the revised label is the removal of the Personal Protective Equipment (PPE) usually listed on product labels, due to the innovative design of the device. According to Levi, “Standard commercial mosquito control applications and vector mitigation protocols (including spraying, fogging, as well as other mosquito traps) typically require users to utilize specific safeguards, including long sleeves, protective gloves, and respirators certified by NIOSH. Under the revised federal registration, given the structural safety of the INZECTO Mosquito Trap, operators can handle and deploy the device without PPE. This operational simplicity offers relief for Professional Pest Management personnel who frequently provide applications when summer temperatures can be excessively hot.” The device uses a geometric, pyramid‑style structure designed to contain water, maintain high internal humidity, and slow evaporation. This creates a stable microenvironment that is appealing to egg-laying female mosquitoes looking for places to rest and deposit eggs. Levi notes that its patented design draws on research about how mosquitoes respond to humidity, surface texture, and protection from air movement, rather than relying on a single factor of attractiveness. Only the interior surface of the trap is covered with a microporous coating that releases micro-doses of adulticide and larvicide over time. Users of the INZECTO trap do not contact any active ingredients, therefore do not need PPE for safety and protection. The exposure of mosquitoes to both adulticide and larvicide affects multiple points in the mosquito life-cycle, especially limiting the development of larvae within the device for three months. Such a combined action of adulticide and larvicide simultaneously prevents the development of resistance that often arises from repetitive use of a single insecticide class. The overall concept is to utilize an ‘Attract-and-Kill Strategy’ by providing the most attractive breeding site for mosquitoes, which reduces oviposition in other water- holding containers. “Our design utilizes mosquito behavior to manage populations effectively for three months,” explains Levi, “Female mosquitoes naturally select localized, humid environments to deposit eggs and rest, which makes the microclimate inside the trap highly competitive against alternative yard containers.” This three-month EPA-validated efficacy in mosquito control supports a proactive, quarterly deployment schedule rather than conventional reactive treatments. Traditional Pest Control frequently initiates applications after localized insect populations have reached peak density. A systematic four-times-a-year maintenance cycle allows public health agencies and property managers to lower mosquito populations year-round. Late autumn deployments, specifically from October to December, assist in suppressing the mosquitoes that would emerge during the following spring. This updated availability arrives amid expanding geographic ranges for vector species, influenced by shifting global climate patterns and prolonged summer seasons. Regulatory trends have simultaneously restricted the allowable volume and residual duration of traditional chemical barrier treatments. The simplicity, efficacy, duration, and mode of action of the trap allow either a stand-alone application or integration with fogging, spraying, or other forms of mosquito control. Ultimately, this new EPA registration of the INZECTO Mosquito Trap confirms the company’s commitment to combining knowledge of insect biology with innovative technology in order to provide effective and long-lasting public health tools with no hazard to humans or the environment.
- May 28, 2026Science
Biointron Launches RushMab as Antibody Production Market Targets $39.8B by 2033
Grand View Research puts the global antibody production market at USD 15.44 billion for 2024, with projections of USD 39.80 billion by 2033, an 11.2 percent compound annual growth rate tied directly to the expansion of biologic drug pipelines and the rising volume of pre-clinical validation work being outsourced to specialist CROs. Biointron Biological Inc., a contract research organization based in Cambridge, Massachusetts, has launched Small-Scale Antibody Expression Packages under the RushMab™ brand, compressing antibody delivery timelines to as few as 10 days for purified, quality-controlled material. Pharma and biotech companies are outsourcing more pre-clinical work than ever before. The antibody contract manufacturing segment alone represented USD 34.72 billion in addressable opportunity as of 2026, per a market report published in April of that year via GlobeNewswire. Speed is now the primary variable. When expression turnaround runs long, candidate screening cycles slip with it, sometimes by weeks, and for research-stage companies working under tight capital constraints, those delays carry real cost. The shift has made fast, small-batch CRO capability a procurement priority rather than a convenience. For more information, visit https://www.biointron.com/antibody-production/rushmab-small-scale-expression-packages.html Recombinant antibody expression converts a sequence file into a functional protein a research team can actually use. Biointron's RushMab™ line covers that process at four delivery speeds. Teams that only need plasmid material can get 100 micrograms of transfection-grade expression plasmids from the RushMab™-Gene package in four days. RushMab™ Super adds purification and delivers antibody with titer detection in eight. Both Mini and Standard packages hit the 10-day mark with full purification: the Mini at a minimum of 100 micrograms, the Standard at over 1 milligram, with endotoxin testing below 1 EU/mg and SDS-PAGE plus SEC-HPLC verification on both. IgG, Fab, VHH, and ScFv formats are all supported, covering the structural range most common in early biologic research. Service details are on Biointron's Small-Scale Antibody Expression Packages page. Speed-to-delivery has become the main competitive axis in small-scale antibody expression. GenScript Biotech Corporation, listed on the Hong Kong Stock Exchange, runs a TurboCHO™ transient expression platform that publishes five-business-day turnaround for select configurations. Sino Biological cites a 10-day gene-to-antibody standard across its high-throughput recombinant service. Biointron competes at that same benchmark with the added breadth of IgG, Fab, VHH, and ScFv support in one service menu. ISO 9001:2015 certification and membership in MassBio – the Massachusetts life sciences industry association – round out the compliance profile that pharmaceutical procurement teams typically require. "As biologic pipelines grow and AI-driven candidate generation accelerates, the wet-lab expression step has become the rate-limiting factor in early research programs," said Mia Deng of Biointron Biological Inc. She noted that RushMab™ was built to keep pace with how fast modern discovery workflows now move. "A 10-day turnaround for a fully purified, endotoxin-tested antibody removes a friction point that used to cost teams weeks between candidate iterations." Biointron was founded in 2012. Since then it has delivered recombinant antibody services to more than 2,500 biotech and pharmaceutical organizations spanning more than 20 countries. In 2025, Scientist.com recognized the company with its Supplier Performance Recognition Award for drug discovery research services. Cambridge, Massachusetts, puts Biointron inside one of North America's most concentrated corridors for biologic research, academic medical centers, pharmaceutical research units, and venture-backed startups, all operating within close proximity and generating consistent demand for fast, reliable CRO output. The full range of Antibody Expression Packages is available on the company's website. About Biointron Biological Inc. Biointron Biological Inc . is a Cambridge, Massachusetts-based contract research organization specializing in antibody discovery, antibody production, stable cell line development, and protein expression services for biotech and pharmaceutical clients worldwide. Founded in 2012 and ISO 9001:2015 certified, Biointron has served more than 2,500 organizations across more than 20 countries.
- May 28, 2026Science
Biointron Launches RushMab Packages to Deliver Purified Antibodies in 10 Days
Antibody production timelines have long been one of the most stubborn bottlenecks in early-stage drug discovery. Researchers who need recombinant proteins for feasibility testing, candidate screening, or assay development have typically waited weeks for material to arrive, time that compounds across every iteration of a research program. Biointron Biological USA Inc . (“Biointron”), a contract research organization specializing in antibody discovery and production services with offices located in Cambridge, Massachusetts, and Piscataway, New Jersey, has released Small-Scale Antibody Expression Packages under the RushMab™ brand, compressing the wait to as few as 4 days for transfection-grade expression plasmids, and 10 days for purified, quality-controlled antibody material. Beyond shortened turnaround time, RushMab™ is designed to support high-throughput antibody expression workflows. This platform can process up to thousands of samples within a single batch, allowing researchers to express, purify, and compare large panels of antibody candidates in parallel. This capability is particularly relevant for early-stage antibody discovery, where rapid candidate prioritization often depends not only on how quickly material can be produced, but also on how many variants can be evaluated side by side. The timing reflects sustained pressure across the biopharmaceutical sector to accelerate pre-clinical workflows. According to Grand View Research, the global antibody production market was valued at approximately USD 15.44 billion in 2024 and is projected to reach USD 39.80 billion by 2033, expanding at a compound annual growth rate of 11.2 percent. For more information, please visit https://www.biointron.com/antibody-production/rushmab-small-scale-expression-packages.html That growth is driven in part by rising demand for rapid, small-batch antibody material to support the growing volume of biologic drug candidates entering early research pipelines. As AI-assisted antibody design tools generate candidate sequences faster than wet-lab validation can keep pace, the pressure on expression turnaround has intensified further. Recombinant antibody expression is the process by which a defined antibody sequence provided as a gene construct or sequence file, is introduced into a host cell system, typically mammalian, to produce functional antibody protein that can be harvested, purified, and used in downstream research. Biointron’s RushMab™ packages are built around this workflow, with four tiers designed to match different research needs: The RushMab™-Gene package delivers 100 micrograms of transfection-grade expression plasmids within four days. The RushMab™-Super package offers purified antibody with titer detection in eight days. The RushMab™-Mini package provides no fewer than 100 micrograms of purified antibody alongside expression plasmids within 10 days, verified by SDS-PAGE and SEC-HPLC analysis. The RushMab™-Standard package delivers more than one milligram of purified antibody with endotoxin levels below 1 EU/mg within the same 10-day window, backed by full SDS-PAGE and SEC-HPLC quality documentation. Speed and throughput have become defining competitive factors in small-scale antibody expression. In early discovery programs, researchers often need to evaluate dozens, hundreds, or even thousands of antibody candidates before selecting leads for deeper characterization. RushMab™ addresses this need by combining fast production timelines with high-throughput batch processing, enabling large candidate panels to be generated and compared in parallel. Biointron’s RushMab™ packages position the company within this competitive tier while extending format flexibility to IgG, Fab, VHH, and ScFv sequences, antibody types that are each suited to distinct research applications and that not all rapid-expression providers accommodate across a single service menu. Researchers today are working faster than ever, and waiting weeks for a small antibody batch can stall an entire program. RushMab™ was built specifically to close that gap. Whether a team needs plasmid-only output in four days or a fully purified, endotoxin-tested antibody in ten, we now have a structured option for each stage of that decision. Biointron was founded in 2012 and has since delivered recombinant antibody services to more than 3,000 biotech and pharmaceutical organizations across more than 20 countries. The company is a member of various life sciences industry associations, such as MassBio (Massachusetts), BioNJ (New Jersey), California Life Sciences, and the UK BioIndustry Association (BIA). Biointron also holds ISO 9001:2015 certification. Its Cambridge, Massachusetts address places it within one of North America’s most active clusters for biologic drug development, where proximity to academic medical centers and pharmaceutical research groups has historically driven demand for responsive CRO services. Biointron received the 2025 Scientist.com Supplier Performance Recognition Award for outstanding delivery of drug discovery research services. The RushMab™ packages are available now through Biointron’s Small-Scale Antibody Expression Packages service page. About Biointron Biointron is a Shanghai-based antibody contract research organization with offices in Cambridge, MA and Piscataway, NJ, specializing in antibody discovery, antibody production, stable cell line development, and protein expression services for biotech and pharmaceutical clients worldwide. Founded in 2012 and ISO 9001:2015 certified, Biointron has served more than 3,000 organizations across 20+ countries.
ALL NEWS
- KBT Packing Expands Packaging Automation Support for Food and Industrial Manufacturers
- KBT Packing Strengthens Packaging Automation Support with Advanced Packaging Machine and Thermoforming Packaging Machine Solutions
- KBT Packing Highlights New Packaging Solutions Designed for Freshness, Protection, and Production Efficiency
- VdoCipher Launches Free Video Compressor for Large Video Files upto 10 GB
- PLM Expands Automotive Technology Portfolio With Acquisition of MotorTablet and CarTablet
- Anthony Joseph Amaradio and His Opinion on How Faith Helps Children's Success
- Team Sports Expands Training Equipment with Xtreme Tumbl Trak
- Boris Mizhen Shares the Reason Why People Prefer Shopping Online During the Holidays
- Meyer Bees Highlights Availability of VSH Italian Queen Bee
- Shieldly Premier Insurance Solutions Expands Insurance Review Services as California Insurance Changes Leave More Residents Reassessing Coverage
- Konstantin vision eyewear center launches seasonal professional eyeglasses adjustments for New York residents
- Innovative Connections Launches Pilot Mentoring Programme For Leaders Navigating Sociopolitical Tension
- 2026 Aluminium Windows and Doors for Sydney Projects: How RS Doors & Windows Supports Delivery
- DR.WOSSEN is deeply engaged in the Chinese market by benchmarking against the high standards of Germany
- CheersYou International Consulting Highlights Growing Focus on Long-Term Admissions Planning
- Jingning She Autonomous County Marks 40th Anniversary with Official Promotional Film
- Fly to the 'Land of Smiles' with AirAsia
- Shanghai Xiongda International Logistics Announces Strategic Expansion with New 10,000-Square-Meter Headquarters Facility
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS